We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.46B
AUM Growth
-$732M
Cap. Flow
-$476M
Cap. Flow %
-10.67%
Top 10 Hldgs %
48.58%
Holding
171
New
10
Increased
26
Reduced
81
Closed
23

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$53M
2
BEAM icon
Beam Therapeutics
BEAM
+$23M
3
SYK icon
Stryker
SYK
+$17.7M
4
ABBV icon
AbbVie
ABBV
+$17.5M
5
BAX icon
Baxter International
BAX
+$14.9M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$204M
2
ARVN icon
Arvinas
ARVN
+$45.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$34.7M
4
VRNA
Verona Pharma
VRNA
+$30.4M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$28.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Technology 0.01%
3 Communication Services 0.01%
4 Consumer Discretionary 0%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COR icon
51
Cencora
COR
$59.9B
$19.8M 0.44%
71,360
-6,162
-8% -$1.55M
RLAY icon
52
Relay Therapeutics
RLAY
$4.34B
$19.3M 0.43%
7,377,292
– –
REGN icon
53
Regeneron Pharmaceuticals
REGN
$70.9B
$18.1M 0.41%
28,523
-2,889
-9% -$1.99M
EHC icon
54
Encompass Health
EHC
$11.1B
$17.5M 0.39%
172,878
-15,644
-8% -$1.53M
ELV icon
55
Elevance Health
ELV
$80.9B
$17.4M 0.39%
40,058
+1,715
+4% +$688K
NTRA icon
56
Natera
NTRA
$38.9B
$16M 0.36%
113,219
-32,457
-22% -$5.22M
CDNA icon
57
CareDx
CDNA
$2.05B
$15.8M 0.35%
889,003
-485,409
-35% -$10.5M
INSP icon
58
Inspire Medical Systems
INSP
$1.46B
$15.8M 0.35%
99,027
-49,451
-33% -$8.95M
PRVA icon
59
Privia Health
PRVA
$3.39B
$15.7M 0.35%
697,308
-255,856
-27% -$5.94M
BAX icon
60
Baxter International
BAX
$11.7B
$15.6M 0.35%
+456,446
New +$14.9M
HOLX
61
DELISTED
Hologic
HOLX
$15.3M 0.34%
247,886
– –
BRKR icon
62
Bruker
BRKR
$8.86B
$14M 0.31%
335,288
-24,300
-7% -$1.26M
ESPR
63
DELISTED
Esperion Therapeutics
ESPR
$14M 0.31%
9,694,064
-250,000
-3% -$461K
THC icon
64
Tenet Healthcare
THC
$16.8B
$12.7M 0.29%
94,722
-15,508
-14% -$2.04M
MGNX icon
65
MacroGenics
MGNX
$285M
$12.6M 0.28%
9,929,963
– –
SIBN icon
66
SI-BONE Inc
SIBN
$771M
$12.2M 0.27%
872,991
-7,988
-0.9% -$129K
TMDX icon
67
Transmedics
TMDX
$2.56B
$11.7M 0.26%
173,710
-19,008
-10% -$1.31M
MASI
68
DELISTED
Masimo
MASI
$11.6M 0.26%
69,808
+45,642
+189% +$7.92M
NEO icon
69
NeoGenomics
NEO
$1.9B
$11.5M 0.26%
1,216,756
+160,960
+15% +$2.01M
INSM icon
70
Insmed
INSM
$23.5B
$11.5M 0.26%
150,550
-107,933
-42% -$8.26M
AXSM icon
71
Axsome Therapeutics
AXSM
$11.8B
$11.2M 0.25%
96,407
-22,523
-19% -$2.57M
JNJ icon
72
Johnson & Johnson
JNJ
$609B
$11.1M 0.25%
67,009
+12,452
+23% +$1.95M
IQV icon
73
IQVIA
IQV
$34.4B
$10.8M 0.24%
61,068
+16,235
+36% +$3.15M
ANNX icon
74
Annexon
ANNX
$950M
$9.95M 0.22%
5,157,290
– –
ONC
75
BeOne Medicines Ltd
ONC
$32.4B
$9.62M 0.22%
35,329
+1,100
+3% +$257K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2025 Portfolio in Review

As of Q1 2025, Bellevue Group held 171 positions worth $4.46B, down 14% from $5.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $476M in Q1 2025, closing 23 positions and reducing 81 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $204M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Bellevue Group opened a new position in Akero Therapeutics worth $50.6M.

  • Bellevue Group's largest Q1 2025 buy was Akero Therapeutics: 1,250,666 shares worth $50.6M.
  • Bellevue Group added most to Beam Therapeutics in Q1 2025, an estimated $23M increase.
  • Bellevue Group's biggest Q1 2025 reduction was Vertex Pharmaceuticals, cutting an estimated $34.7M.
  • Bellevue Group fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $204M.
  • Bellevue Group's ten largest holdings make up 49% of its $4.46B portfolio in Q1 2025.
  • Bellevue Group opened 10 new positions and closed 23 in Q1 2025.
  • Bellevue Group's portfolio value fell 14% quarter-over-quarter to $4.46B.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.